PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis Research

Executive Summary: PA-824 (SKU A1736) is a bicyclic nitroimidazole derivative with potent antimycobacterial activity, active against both replicating and non-replicating Mycobacterium tuberculosis (M. tuberculosis) strains, including drug-resistant variants [APExBIO]. It inhibits ketomycolate biosynthesis, a key step in mycolic acid production, and undergoes enzymatic nitro-reduction to release intracellular nitric oxide, contributing to bactericidal action (Rahman et al., 2026). Minimum inhibitory concentration (MIC) values range from 0.015 μg/ml to 0.25 μg/ml under standard in vitro conditions. PA-824 is DMSO-soluble (≥17.85 mg/mL), insoluble in water and ethanol, and provided at ≥98% purity with complete quality documentation. It is central for research in drug-resistant tuberculosis and mechanistic studies of nitroimidazole antimycobacterial mechanisms.

Biological Rationale

Tuberculosis (TB) remains a leading cause of global morbidity and mortality, with the rise of drug-resistant strains posing a major challenge to public health (Rahman et al., 2026). The cell wall of M. tuberculosis is rich in mycolic acids, synthesized via the ketomycolate pathway, which confers resistance to antibiotics and immune defenses. Innovative antimycobacterial agents are required that can target both active and latent forms of the bacterium. PA-824, developed and supplied by APExBIO, represents a rational advance by directly targeting ketomycolate biosynthesis and inducing intracellular nitric oxide release, mechanisms essential for overcoming both replicating and non-replicating TB persisters. This mechanism complements conventional TB therapies and addresses gaps in the treatment of multidrug-resistant and latent TB infections. For a broader discussion on the molecular rationale and clinical translation, see this recent article, which this review extends by providing updated, peer-reviewed benchmarks and practical workflow integration guidance.

Mechanism of Action of PA-824

PA-824 is a nitroimidazole prodrug that requires enzymatic activation within M. tuberculosis cells. Its mechanism involves dual action:

• Inhibition of ketomycolate biosynthesis, blocking the production of cell wall mycolic acids (Rahman et al., 2026).
• Enzymatic nitro-reduction leads to intracellular release of nitric oxide (NO), which disrupts the electron transport chain and impairs bacterial bioenergetics (Rahman et al., 2026).

This dual mode of action allows PA-824 to kill both actively replicating and dormant, non-replicating M. tuberculosis. By targeting essential metabolic pathways, PA-824 maintains efficacy against drug-resistant strains, which often evade conventional therapies. For further mechanistic insights, this article describes dual-action potency, which this dossier specifies with recent quantitative MIC/IC50 data and updated resistance benchmarks.

Evidence & Benchmarks

• PA-824 demonstrates minimum inhibitory concentrations (MIC) between 0.015 μg/ml and 0.25 μg/ml against M. tuberculosis H37Rv and multidrug-resistant clinical isolates under standard in vitro conditions (Rahman et al., 2026).
• The compound’s IC₅₀ is less than 2.8 μM for M. tuberculosis in DMSO-based assays at 37°C, 5% CO₂ (APExBIO).
• Enzymatic nitro-reduction of PA-824 within the mycobacterial cell is required for bactericidal activity, with nitric oxide release confirmed by NO-sensitive fluorescent probes (Rahman et al., 2026).
• PA-824 retains efficacy against both replicating and non-replicating (hypoxic, nutrient-starved) TB populations (Rahman et al., 2026).
• Synergistic bactericidal effects are observed when combined with terminal oxidase inhibitors such as telacebec (Q203) and ND-011992 (Rahman et al., 2026).
• PA-824 is delivered as a solid with a molecular weight of 359.26 and chemical formula C₁₄H₁₂F₃N₃O₅ (APExBIO).
• Solubility in DMSO is ≥17.85 mg/mL; insoluble in water and ethanol (APExBIO).
• Supplied at ≥98% purity, with comprehensive QC (COA, HPLC, NMR, MSDS) for reproducible research (APExBIO).

Applications, Limits & Misconceptions

PA-824 is primarily applied in preclinical and translational research addressing drug-resistant and latent TB. Its validated performance in cell viability, drug-resistance, and metabolic pathway assays makes it a standard for mechanistic and antimicrobial efficacy studies. For scenario-based laboratory solutions, see this workflow guide, which this article updates with recent mechanistic and resistance interaction data.

Common Pitfalls or Misconceptions

• PA-824 is not effective against non-mycobacterial pathogens or fungi; its spectrum is confined to Mycobacterium species.
• It does not substitute for combination therapy in clinical TB management; monotherapy risks resistance emergence.
• Solubility limitations require DMSO as a solvent; it is not compatible with aqueous or ethanol-based protocols.
• PA-824 is not a direct clinical drug; it is for research use only and not for human therapeutic administration.
• Stability is compromised above -20°C or in solution beyond short-term storage; always follow supplier guidance.

Workflow Integration & Parameters

PA-824 is supplied as a solid by APExBIO (SKU A1736), and should be reconstituted in DMSO to achieve a working stock of at least 17.85 mg/mL. For MIC or cell-based assays, dilute DMSO stock into appropriate media, ensuring final DMSO concentrations are ≤1% v/v to minimize cytotoxic effects. Store solid compound at -20°C and use solutions within 1–2 weeks for optimal activity. Quality documentation (COA, HPLC, NMR, MSDS) is provided for batch-to-batch reproducibility and regulatory compliance. Researchers should reference validated protocols for MIC and synergy testing, particularly when combining with terminal oxidase inhibitors. For expanded protocol optimization and Q&A scenarios, see this expert guide, which this dossier supplements with updated peer-reviewed benchmarks and workflow parameters.

Conclusion & Outlook

PA-824 is a validated, high-purity bicyclic nitroimidazole derivative central to modern tuberculosis research. Its dual mechanism—ketomycolate biosynthesis inhibition and nitric oxide-mediated bacterial killing—enables reproducible, benchmarked activity against drug-resistant and latent TB forms. Ongoing research continues to define optimal combinations and mechanistic synergies, supporting rational TB regimen development. For full technical specifications and ordering, refer to the PA-824 product page. Future studies will further clarify the molecular basis of resistance suppression and new application domains for this research compound.